lysergic acid diethylamide + psilocybin

Lysergic acid diethylamide (LSD) and psilocybin are serotonergic psychedelic compounds being evaluated in a retrospective observational study at the University Hospital, Geneva (Geneva University Hospitals) for the treatment of various treatment-resistant psychiatric conditions. These substances act primarily as partial agonists at the serotonin 5-HT2A receptor, inducing profound alterations in perception, cognition, and emotion. In the clinical setting of psychedelic-assisted psychotherapy (PAP), these drugs are administered in controlled sessions (typically 100 µg for LSD or 25 mg for psilocybin) to facilitate therapeutic breakthroughs in patients with major depressive disorder, anxiety disorders, substance use disorders, and post-traumatic stress disorder. This program operates under Switzerland's special access framework for the limited medical use of prohibited substances, aiming to generate real-world evidence on the safety and therapeutic potential of psychedelics in clinical practice.

Other names

LSD + psilocybinpsychedelic-assisted psychotherapyPAP